Monitor for the actual sale via subsequent Form 4 filings. While the 10b5-1 plan reduces opportunistic signaling, the large dollar amount by an officer could pressure near-term sentiment. Watch for any acceleration of insider selling or changes to the trading plan.
Price Chart
Executive Summary
Officer Abraham N. Ceesay filed a Form 144 indicating intent to sell 99,480 shares of Rapport Therapeutics (RAPP), valued at approximately $4.0 million. The sale is pre-scheduled under a Rule 10b5-1 trading plan dated March 27, 2026, but the size is material relative to recent insider activity and represents a notable increase in planned selling by a key insider.
Key Facts
- Officer Abraham N. Ceesay intends to sell 99,480 shares of common stock.
- Estimated aggregate market value of the proposed sale is $4,017,997.20.
- Shares were acquired as compensation (performance awards) on December 2, 2022.
- The sale is pursuant to a Rule 10b5-1 trading plan established on March 27, 2026.
- Recent insider activity (30 days) includes 6 sells totaling $743K; this single filing is ~5.4x that total.
Financial Impact
Proposed sale of ~$4.0M worth of shares, representing approximately 0.21% of RAPP's $1.9B market cap.
Risk Factors
- Additional insider selling beyond this planned sale could signal deteriorating confidence.
- The stock may face selling pressure as the market absorbs the planned distribution.
- Negative sentiment from insider selling may outweigh the pre-planned nature of the trade.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001958244-26-000411 |
| Document: 0001958244-26-000411-index.html | 0001958244-26-000411 |
| Document: 0001958244-26-000411.txt | 0001958244-26-000411 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | Insider Cluster | $26.00 | awaiting T+5 | — | $25.93 (−0.27%) |
Oct 22, 2026 4d ago | Insider Cluster | $27.33 | awaiting T+5 | — | $25.93 (−5.12%) |
Oct 21, 2026 4d ago | Insider Buy | $26.53 | awaiting T+5 | — | $25.93 (−2.26%) |
Oct 20, 2026 6d ago | 8-K | $29.37 | awaiting T+5 | — | $25.93 (−11.71%) |
Oct 6, 2026 19d ago | 144 | $30.86 $28.33 | ▲ +8.20% | ▲ +7.22% | $25.93 (+15.98%) |
Oct 1, 2026 24d ago | Insider Cluster | $32.17 $30.65 | ▼ −4.72% | ▼ −5.89% | $25.93 (−19.40%) |
Aug 26, 2026 8w ago | Insider Cluster | $50.83 $47.65 | ▼ −6.26% | ▼ −6.52% | $25.93 (−48.99%) |
Aug 5, 2026 11w ago | 8-K | $42.44 $47.73 | ▲ +12.46% | ▲ +12.11% | $25.93 (−38.90%) |
Jul 1, 2026 16w ago | Insider Cluster | $38.97 $41.75 | ▲ +7.13% | ▲ +5.77% | $25.93 (−33.46%) |
Jun 30, 2026 16w ago | 144 | $39.39 $39.72 | ▲ +0.84% | ▲ +0.58% | $25.93 (−34.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers